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Abstract 
Background: Arginase competes with endothelial nitric oxide synthase (eNOS) for the 
substrate L-arginine and decreases NO production. This study investigated regulatory 
mechanisms of arginase activity in endothelial cells and its role in atherosclerosis. 
Methods and results: In human endothelial cells isolated from umbilical veins, thrombin 
concentration- and time-dependently stimulated arginase enzymatic activity, reaching 1.9-
fold increase (p<0.001) at 1 U/ml for 24 hours. The effect of thrombin was prevented by 
C3 exoenzyme or HMG-CoA reductase inhibitor fluvastatin that inhibit RhoA or by 
ROCK inhibitors Y-27632 and HA-1077. Adenoviral expression of constitutively active 
RhoA or ROCK mutants enhanced arginase activity (ca. 3-fold, p<0.001) and the effect of 
active RhoA mutant was inhibited by the ROCK inhibitors. Neither thrombin nor the 
active RhoA/ROCK mutants affected arginase II protein level, the only isozyme detectable 
in the cells. Moreover, a significantly higher arginase II activity (1.5-fold, not the protein 
level) and RhoA protein level (4-fold) were observed in atherosclerotic aortas of ApoE-/- 
compared to wild type mice. Interestingly, L-arginine (1 mmol/L), despite a significantly 
higher eNOS expression in aortas of ApoE-/- mice, evoked a more pronounced contraction 
which was reverted to a greater vasodilation by the arginase inhibitor L-norvaline (20 
mmol/L) compared to the wild type animals (n=5, p<0.001).    
Conclusions: Thrombin enhances arginase activity via RhoA/ROCK in human endothelial 
cells. Higher arginase enzymatic
 
activity is involved in atherosclerotic endothelial 
dysfunction in ApoE-/- mice. Targeting vascular arginase may represent a novel 
therapeutic possibility for atherosclerosis.   
 
Key words: Atherosclerosis - cells – cardiovascular disease – endothelium-derived factors – 
signal transduction  
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Condensed Abstract 
    In human endothelial cells, thrombin stimulates arginase enzymatic activity which was 
prevented by inhibition of RhoA/ROCK pathway. Adenoviral expression of active mutant of 
RhoA or ROCK mimics thrombin’s effect. Arginase activity, eNOS expression and RhoA 
level are increased in atherosclerotic aortas of ApoE-/- mice. Inhibition of arginase by L-
norvaline caused a greater vasorelaxation to L-arginine in atherosclerotic aortas of ApoE-/- 
compared to wild type mice. Thus, higher arginase enzymatic activity is involved in 
endothelial dysfunction in atherosclerosis. Targeting arginase in the vasculature may 
represent a novel therapeutic possibility for atherosclerosis.  
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Vascular endothelial cells produce nitric oxide (NO) from the precursor substrate L-
arginine via endothelial NO-synthase (eNOS). NO plays a critical role in regulation of 
vascular tone and maintenance of vascular integrity.1
 
Decreased production or bioavailability 
of NO is a common mechanism involved in the pathogenesis of various cardiovascular 
diseases such as atherosclerosis, hypertension and diabetic vasculopathy.2,3 Among other 
mechanisms such as regulation of co-factors, eNOS gene expression, and enzymatic 
activation, the availability of the substrate L-arginine is an important limiting factor for NO 
production.4 Emerging evidence demonstrates that arginase, an enzyme in the urea cycle, 
competes with NOS for the substrate L-arginine and thus reduces NO production as shown in 
macrophages and vascular endothelial cells.4-7 This mechanism has been recently implicated 
in diabetic erectile dysfunction, aging-associated endothelial dysfunction, allergen-induced 
deficiency of NO and airway hyperresponsivness in asthma.8-10 
Two types of mammalian arginase namely arginase I
 
and
 
II encoded by different genes 
exist.11 Arginase I, located in the cytoplasm, is expressed most abundantly in the liver, while 
arginase II is a mitochondrial enzyme and is mostly expressed in extrahepatic tissues 12-14. 
Recent studies demonstrate that the activity of arginase can be regulated in many cell types 
including vascular endothelial cells, smooth muscle cells and macrophages by various 
cytokines.7,15,16 Depending on cell types studied, activity or gene expression of the two 
isozymes are either constitutively expressed or induced, which regulates NO production. In 
porcine coronary and rat aortic endothelial cells arginase I is constitutively expressed,7,17 
whereas arginase II is induced in response to lipopolysaccharide.17 In human diabetic corpus 
cavernosum arginase II expression is significantly increased and inhibition of this enzyme 
enhanced NO-dependent relaxation of penile corpus cavernosum smooth muscle.8 These 
observations suggest a potential role of arginase II in negative regulation of NO production. 
However, the exact type of the isozymes expressed in human vascular endothelial cells has 
not yet been elucidated. Moreover, the regulatory mechanisms of arginase activity in 
endothelial cells and in atherosclerotic blood vessels are unknown.   
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Recent research provides compelling evidence that the small G-protein RhoA plays an 
important role in regulation of various cellular functions in vasculature.18,19 With respect to 
its role in the regulation of NO production, studies from our own and other laboratories 
demonstrated that RhoA via its downstream effector ROCK plays an important role in 
regulation of eNOS gene expression and enzyme activity.19-21 These data suggest that 
RhoA/ROCK may affect endothelial function at multiple levels. Therefore, this study was 
designed to determine whether RhoA/ROCK pathway is also involved in regulation of 
arginase activity or expression in cultured human endothelial cells and whether arginase 
plays a role in endothelial dysfunction in atherosclerosis. 
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Materials and Methods 
Materials 
     All reagents were purchased from Calbiochem (Luzern, Switzerland) except the following: 
Fluvastatin was provided by Novartis (Basel, Switzerland); anti-RhoA monoclonal antibody 
from Santa Cruz Biotechnology, Inc. (Nunningen, Switzerland); anti-arginase I antibody 
from BD Transduction Laboratory; anti-arginase II rabbit polyclonal antibody was generated 
by Eurogentech, S.A, by immunization with a synthesized peptide containing the 16 C-
terminal amino acid (AA 339 –354) of human arginase II; anti-α-tubulin antibody from 
Sigma; anti-mouse and –rabbit IgG alkaline phosphatase (AP) conjugate were purchased 
from Promega (Wallisellen, Switzerland); BCIP/NBT solution was purchased from Upstate 
Biotechnology Inc. (Lucerne, Switzerland). Endothelial cell growth supplement (ECGS) pack 
from PromoCell GmbH (Allschwill, Switzerland); all cell culture media and materials were 
purchased from Gibco BRL (Basel, Switzerland). 
 
Cell Culture 
     Endothelial cells were isolated from human umbilical veins (HUVEC) as previously 
described.21 Cells of 1st to 4th passages were used.    
 
Generation of Recombinant Adenoviruses (rAd) and Adenoviral Infection 
     Generation of recombinant adenovirus expressing HA-tagged RhoA, ROCK mutants 
driven by the cytomegalovirus (CMV) promoter and the adenoviral infection of HUVECs 
were described previously.21 
 
Animals 
     13 male apolipoprotein E-deficient (ApoE-/-) mice and 13 male C57BL/6J wild type 
control mice (4-weeks-old) were obtained from Jackson Laboratory (USA). To accelerate 
lesion formation, animals were fed a Western type diet (Harlan TD88137, 21.2% total fat and 
0.2% cholesterol) for 4 months.22 At 5 months of age, animals were anesthetized with 
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pentobarbital (100 mg/kg i.p.), the entire aorta from the heart to the iliac bifurcation were 
removed, placed into cold (4oC) Krebs bicarbonate solution, dissected free from fat and 
adhering perivascular tissue. The isolated aorta was cut into two parts. One part was used for 
analysis of arginase activity and the other for protein expression by Western blot. The 
isolated vessel was snap-frozen in liquid nitrogen. The tissues were homogenized and 
sonicated in arginase lysis buffer (see below) for arginase activity assay or in extraction 
buffer for analysis of protein expression by Western blot21. Protein concentration was 
determined by Bradford method (Bio-Rad). Animal handling and experimentation were 
approved by local animal ethical committee.  
 
Measurement of arginase activity 
     Arginase activity in the cells and aortic tissue lysates was measured by colorimetric 
determination of urea formed from L-arginine by a modification of published procedure.16  
 
Western blot for eNOS and arginase expression   
     HUVEC and mouse aortic tissue extract preparation, SDS-PAGE, transfer of SDS gels to 
an Immobilon-P membrane (Millipore) were performed as previously described.21 The 
resultant membrane was incubated overnight with the corresponding primary antibody at 
4oC with gentle agitation after blocking with 5% skimmed milk. The protein was decorated 
with a corresponding anti-mouse or anti-rabbit AP-conjugated secondary antibody and 
detected using BCIP/NBT substrate solution. Quantification of the signals was performed 
using NIH Image 1.62 software. In all the plotted graphics, each point represents the average 
value from three to five independent experiments. 
 
eNOS activity assay  
 eNOS activity was measured by L-citrulline production in HUVECs as previously 
described. 21    
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Vascular reactivity studies 
 The isolated descending thoracic aortas with intact endothelium from wild type and 
ApoE-/- mice were cut into rings (3 mm in length) which were suspended in a Multi-
Myograph System (Model 610M, Danish Myo Technology A/S, Denmark) as described.23 To 
study the role of arginase in modulation of eNOS function, aortic rings with endothelium in 
parallel were incubated with or without the arginase inhibitor L-norvaline (20 mmol/L) for 1 
hour,5-9 and then contracted with norepinephrine (0.3 µmol/L). L-arginine (I mmol/L) was 
added on top of the contraction.   
 
Statistics 
     Data are given as mean±SEM. In all experiments, n equals the number of experiments or 
animals. Statistical analysis was performed with unpaired t test or ANOVA with Dunnett or 
Bonferroni post-test. Differences in mean values were considered significant at p<0.05. 
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Results 
 
Thrombin stimulates arginase activity in human endothelial cells   
     Stimulation of HUVECs with various concentrations of thrombin (0.1 U/ml to 2 U/ml) for 
24 hours enhanced arginase activity with the maximum effect at the concentration of 1 U/ml 
(1.9-fold increase above control, n=9, P<0.001, Fig. 1). Therefore, 1 U/ml of thrombin was 
used in the following experiments. The cells were then stimulated with thrombin (1 U/ml) at 
different time points from 5 minutes to 24 hours. As demonstrated in Fig. 2, a significant 
increase in arginase activity was observed after 18 to 24 hours exposure of the cells to 
thrombin with a maximum effect at 24 hours (1.9-fold, n=3, p<0.001). 
 
The role of RhoA /ROCK in regulation of arginase activity   
     As shown in Fig. 3A, stimulation of arginase activity by thrombin (1 U/ml, 24 hours) in 
endothelial cells was inhibited by HMG CoA reductase inhibitor fluvastatin (1 µmol/L) or 
ROCK inhibitor Y-27632 (10 µmol/L) at the concentrations that inhibit RhoA or ROCK as 
shown by our previous study.24 Neither thrombin nor the inhibitors significantly influenced 
arginase II protein level (Fig. 3B, arginase I was not detectable in the cells). Stimulation of 
arginase activity by thrombin was also inhibited by C3 exoenzyme (20 µg/mL) or by another 
ROCK inhibitor HA-1077 (10 µmol/L, Fig. 3C; n=5, p<0.001 vs. thrombin alone), further 
demonstrating the role of Rho/ROCK pathway in thrombin-stimulated arginase activity in 
the cells. It is to notice that exposure of the cells to thrombin at 1 U/ml time-dependently 
suppressed eNOS protein level over 24 hours, an effect that was already significant at 6 hours 
(Fig. 3D). Furthermore, adenovirus-mediated expression of the active mutant of RhoA 
(Rho63) or ROCK (CAT) enhanced arginase activity in the cells, whereas the negative 
mutant of RhoA (Rho19) or ROCK (RB) alone had no effect (Fig. 4A, n=7). Again, the 
arginase II protein level in the cells were not affected by the mutants (Fig. 4B, n=7). The 
increase in arginase activity stimulated by the active Rho63 mutant was abolished by the two 
different ROCK inhibitors Y-27632 (10 µmol/L) or HA-1077 (10 µmol/L, Fig. 4C). The 
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inhibitors alone had no significant effects on the basal arginase activity (Fig. 4C). We have 
previously shown 21 that eNOS protein level is markedly down-regulated by the active RhoA 
or ROCK mutants 24 hours after transduction.  
 
Increased arginase activity and RhoA expression in atherosclerosis  
     Given the above observations, we tested whether arginase activity is increased in 
atherosclerosis. ApoE-/- atherosclerotic mice were used for this purpose. Indeed, ApoE-/- 
mice fed a cholesterol rich diet for 4 months developed atherosclerotic lesions throughout the 
aorta,22 and showed a significant higher arginase activity than aortas isolated from age-
matched wild type mice (1.5-fold increase, n=5, p<0.01, Fig. 5A), In addition, the arginase II 
protein level was comparable in the aortas of the two groups and arginase I protein was not 
detectable in the mice aortas (data not shown). Interestingly, RhoA protein level was 
remarkably increased (4-fold) in the aortas of ApoE-/- mice as compared to wild type animals 
(Fig. 5B).  
 
Arginase and eNOS activity  
The role of arginase in regulating eNOS activity was further investigated. In HUVECs, 
eNOS activity as measured by L-citrulline production was blunted by eNOS inhibitor L-
NAME (0.1 mmol/L) and also by thrombin (1 U/ml, 24 hours, n=5, 50±9% decrease, 
P<0.001, Fig. 6A). Co-treatment of the cells with arginase inhibitor L-norvaline5 (20 
mmol/L, 24 hours), however, did not significantly reverse eNOS activity (Fig. 6A). In mouse 
aortas, L-arginine (1 mmol/L) caused vasoconstriction (in contrast to rats in which L-arginine 
caused vasorelaxation, data not shown) that was more pronounced in ApoE-/- (38±6%) than 
in wild type animals (17±4%, n=5, p<0.01, Fig. 6B), although eNOS expression was 
significantly higher in ApoE-/- than in wild type mice (Fig. 6C, p<0.05). Remarkably, the 
contraction was converted to a more pronounced relaxation by the arginase inhibitor L-
norvaline (20 mmol/L, 1 hour) in atherosclerotic ApoE-/- mice (-21±5%) than in wild type 
animals (-6±2%, Fig. 6B, n=5, p<0.001).    
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Discussion 
Emerging evidence demonstrates that arginase is present in various cell types and is 
involved in negative regulation of NO production as reported in macrophages25-27 and 
endothelial cells.7,17,28 Our present study demonstrates that in human endothelial cells, 
arginase activity is significantly induced by thrombin. The induction of arginase activity can 
be inhibited by the HMG-CoA reductase inhibitor fluvastatin, which inhibits RhoA 
activation by geranylgeranylation of the enzyme19, and also by C3 exoenzyme which 
inactivates RhoA by ADP ribosylation29. Moreover, inhibition of ROCK, a downstream 
effector of RhoA, either by Y-27632 or HA-1077 abolished the thrombin’s effect, suggesting 
that thrombin stimulates arginase activity in human endothelial cells through RhoA/ROCK 
pathway. This conclusion is supported by the experiments showing that adenovirus-mediated 
ectopic expression of the constitutively active mutant of RhoA (Rho63) or ROCK (CAT), but 
not the negative mutants, significantly enhanced arginase activity in the cells. Furthermore, 
the effect of Rho63 was abolished by the ROCK inhibitor Y-27632 or HA-1077.    
Two isoforms of arginases namely arginase I and II were reported to be expressed in 
vascular endothelial cells. In endothelial cells of porcine coronary arterioles and rat aortas, 
arginase I is constitutively expressed,7,17 whereas arginase II is inducible in response to 
lipopolysaccharide or cytokines.17 Our present study, however, showed abundant basal level 
of arginase II, whereas arginase I is not detectable in HUVEC, suggesting that arginase II is 
the major isozyme in HUVECs. It is to note that neither thrombin nor the active mutants of 
RhoA/ROCK did modulate arginase II expression (arginase I is not inducible in the cells), 
suggesting that activation of arginase by thrombin or active RhoA/ROCK mutants occurs at 
the level of enzyme activity rather than on gene expression. Similar findings were also 
reported in rat endothelial cells, where expression of arginases was not modified by 
cytokines, although the enzymatic activity was stimulated.30 It is conceivable that the 
enzyme might be modified biochemically by RhoA/ROCK pathway, that either alters the 
enzymatic activity or the affinity of the enzyme to its substrate. A third isoform of arginase 
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might exist in endothelial cells and cannot be ruled out under our experimental condition. 
This aspect certainly warrants further investigation. 
Furthermore, we demonstrated that arginase enzymatic activity was significantly 
increased in atherosclerotic aortas of ApoE-/- mice. The higher arginase activity in the 
atherosclerotic aortas was associated with higher RhoA protein level suggesting a role of 
RhoA in upregulation of arginase activity. A definite characterization of the role of RhoA in 
stimulation of arginase activity in atherosclerosis in vivo could not be performed at this stage 
due to lack of specific RhoA inhibitors applicable in living mice. Nevertheless, the results 
obtained from cultured HUVECs support the role of RhoA in stimulation of arginase activity. 
Similar to cultured HUVECs, no difference in arginase II expression was observed between 
control mice and atherosclerotic ApoE-/- mice, and arginase I was not detectable in the mice 
aortas (data not shown), suggesting an upregulation of arginase II enzymatic activity in 
atherosclerosis.  
Previous studies have indicated an important role of increased arginase activity, even a 
moderate increase of 1.5 to 2-fold, in endothelial dysfunction in aged rats and in human 
diabetic erectile dysfunction,8,9. We further investigated the role of increased arginase 
activity in regulating NO production in cultured endothelial cells and in atherosclerotic aortas 
of ApoE-/- mice. In HUVECs treated with thrombin, eNOS activity was significantly 
reduced. However, this reduction of eNOS activity was not significantly reversed in the 
presence of arginase inhibitor L-norvaline. It is most likely due to the fact that eNOS protein 
level was simultaneously suppressed by thrombin, as demonstrated by figure 3D and also by 
our previous studies20,21. Alternatively, inhibition of co-factors of eNOS by thrombin might 
also be involved.     
To our surprise, L-arginine induced vasoconstriction in mice aorta, which contrasts with 
the observation in rats (data not shown and see ref. 9) and humans31, where it evoked 
vascular relaxation. The contraction induced by L-arginine is much more pronounced in 
atherosclerotic ApoE-/- mice compared to control animals. The results may implicate that in 
the mice aortas, particularly in the atherosclerotic ApoE-/- aortas, L-arginine may be 
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metabolized by arginase to certain vasoconstrictive intermediate products. Most interestingly, 
the contractions were converted to relaxations in the presence of the arginase inhibitor L-
norvaline, an effect which was significantly greater in atherosclerotic ApoE-/- mice 
compared to wild type animals, demonstrating a dominant role of increased arginase activity 
in regulation of endothelial NO production in atherosclerosis. It is worth to mention that 
eNOS gene expression is significantly higher in atherosclerotic aortas (see figure 6C), further 
supporting the concept that endothelial dysfunction in atherosclerosis is due to a decreased 
NO bioavailability32. The higher eNOS expression in atherosclerosis would make an efficient 
NO production possible, when arginase is inhibited. This may implicate arginase as a 
potential therapeutic target for treatment of atherosclerotic vascular disease. It is also 
important to point out that eNOS protein level was not suppressed in atherosclerotic aortas of 
ApoE-/- mice despite higher RhoA level in these blood vessels. It is conceivable that the 
suppressing effect of RhoA on eNOS protein expression might be compensated by other 
mechanisms in vivo.   
In conclusion, our present study provides evidence for the role of RhoA/ROCK pathway 
in stimulation of arginase activity in human endothelial cells. The increased arginase activity 
is associated with higher RhoA expression and is involved in endothelial dysfunction in 
atherosclerosis. Targeting arginase in the vasculature may represent a novel therapeutic 
strategy for treatment of atherosclerosis. 
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Legends to the Figures 
 
Figure 1. Thrombin dose-dependently stimulates arginase activity in HUVECs. 
HUVECs were first serum starved in 0.2% FCS culture medium for 24 h, followed by 
treatment with various concentrations of thrombin as indicated for 24 h. Cells were then 
extracted in arginase lysis buffer and subjected to arginase activity assay as described in 
materials and methods. Columns represent mean ± SEM of 9 experiments (*P<0.05, 
**P<0.01, ***P<0.001 vs. untreated cells, i.e. dose zero). 
 
Figure 2. Time course of thrombin-induced arginase activity. HUVECs were treated with 
thrombin (1 U/ml) for different times as indicated, extracted and assayed for arginase 
activity. Columns represent mean ± SEM of 3 experiments (*P<0.05, ***P<0.001 vs. 
untreated cells, i.e. time zero). 
 
Figure 3.  Thrombin induces arginase activity via RhoA/ROCK. (A) stimulation of 
arginase activity by thrombin (1 U/ml, 24 hours) was inhibited by pretreatment of the cells 
with fluvastatin (FS, 1 µmol/L) or Y-27632 (Y, 10 µmol/L) for 1 h 30 minutes or (C) by C3 
exoenzyme (20 µg/mL, 20 hours) or HA-1077 (10 µmol/L, 1 hour). (B) A representative blot 
revealing arginase II expression was not modified by various substances used in panel A (the 
expression of arginase I was not detectable in HUVECs). Columns represent mean ± SEM of 
5 independent experiments. (D) eNOS protein level was significantly decreased after 6 hours 
of exposure to thrombin (1 U/ml). ***P<0.001 for comparison between groups as indicated 
or vs. control (0 h) in panel D. 
 
Figure 4. Active RhoA or ROCK stimulates arginase activity. (A) HUVECs were infected 
with recombinant adenovirus (rAd) expressing HA-tagged LacZ, active RhoA (Rho63), 
dominant negative RhoA (Rho19), active ROCK (CAT) or dominant negative ROCK (RB) 
as indicated, at titers ranging from 100 to 150 multiplicity of infection (MOI), and incubated 
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in 0.2% FCS RPMI-1640 supplemented with ECGS for 48 h. Cells were then extracted 
without any treatment and assayed for arginase activity or (B) subjected to Western blot for 
arginase expression. A representative blot revealing arginase II expression is shown in B. 
Columns represent mean ± SEM of 7 independent experiments. (C) Rho63 induced 
activation of arginase activity was inhibited by the ROCK inhibitors Y-27632 (Y) or HA-
1077 (HA). ***P<0.001 for comparison between groups as indicated or vs. LacZ.  
 
Figure 5. Increased arginase activity and RhoA level in atherosclerotic aortas of ApoE-
/- mice: The isolated aorta was cut in two sections. One section was homogenized and 
sonicated in arginase lysis buffer for analysis of arginase activity (A), the other section in 
extraction buffer for analysis of RhoA expression by Western blot (B). The equal amount of 
protein loading was ensured by ponceau S staining of the membrane after protein transfer. 
Each lane in panel B represents aortic sample from one individual animal. WT: wild type. 
*P<0.05 and **P<0.01 vs. WT.   
 
Figure 6: Regulation of eNOS activity by arginase: (A) In cultured HUVECs, the eNOS 
inhibitor L-NAME (LN, 0.1 mmol/L) or thrombin (Thr, 1 U/ml, 24 hours) decreased eNOS 
activity as measured by L-citrulline production, which was not significantly reversed in the 
presence of arginase inhibitor L-norvaline (20 mmol/L, 24 hours, n=5). (B) In aortic rings 
pre-contracted with norepinephrine (0.3 µmol/L), L-arginine (1 mmol/L) caused a more 
pronounced vasoconstriction in ApoE-/- mice than in wild-type (WT) animals. In the 
presence of arginase inhibitor L-norvaline the contractions were converted to a greater 
vascular relaxation in ApoE-/- mice than in WT animals (n=5). (C) eNOS expression was 
significantly higher in ApoE-/- mice than in the WT animals. *P<0.05, **P<0.01 and 
***P<0.001 vs. control or WT.  
 






